HONG KONG and STANFORD, Calif., June 12, 2026
Simcere Pharmaceutical Group Limited has entered into a strategic research collaboration agreement with Stanford Medicine to advance the discovery and development of innovative therapies for idiopathic pulmonary fibrosis (IPF), a devastating chronic lung disease with limited treatment options and poor long-term survival rates. The collaboration will focus on an exploratory research program aimed at developing a first-in-class therapeutic candidate targeting key biological mechanisms involved in pulmonary fibrosis. Under the terms of the agreement, Simcere will fully fund the exploratory research activities and, upon successful completion of the project, will obtain an exclusive license and 100% global rights to commercialize the resulting product. The partnership reflects Simcere’s continued commitment to strengthening its innovation-driven pipeline and expanding its presence in high-value therapeutic areas with significant unmet medical needs.
Collaboration Targets Major Unmet Need in Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a progressive interstitial lung disease characterized by irreversible scarring of lung tissue, leading to declining lung function, respiratory failure, and premature death. Despite recent advances in disease management, currently available therapies are unable to reverse fibrosis, leaving patients with limited treatment options. The disease remains one of the most challenging respiratory disorders, with a median survival of approximately three years following diagnosis and a five-year survival rate ranging between 20% and 40%.
Through this collaboration, Simcere and Stanford Medicine aim to develop a highly targeted therapeutic approach capable of addressing the underlying disease mechanisms driving fibrosis progression. The project is expected to leverage cutting-edge discoveries in chemical biology and translational medicine to identify novel treatment opportunities that could significantly improve outcomes for patients suffering from this life-threatening condition.
World-Class Scientific Expertise Drives First-in-Class Innovation
Advertisement
The research program will be led by renowned scientists from the Stanford Innovative Medicines Accelerator, including Professor Chaitan Khosla and Professor Cui Bianxiao, two internationally recognized experts in chemical biology and fibrosis research. Khosla, a member of the U.S. National Academy of Sciences and Director of the Innovative Medicines Accelerator, is known for his pioneering work in LYTAC-related technologies and innovative therapeutic platforms. Bianxiao is widely recognized for her research into fibrosis-related biological targets and has received prestigious honors including the NIH New Innovator Award.
By combining Stanford’s breakthrough scientific capabilities with Simcere’s drug development expertise, the collaboration seeks to accelerate the translation of laboratory discoveries into clinically relevant therapies. Industry observers view such academic-industry partnerships as increasingly important for advancing next-generation medicines and overcoming scientific barriers associated with complex diseases.
Strengthening Simcere’s Innovation 2.0 Strategy
The agreement represents the second first-in-class global innovation project established between Simcere Pharmaceutical and Stanford Medicine, highlighting the growing strategic relationship between the two organizations. According to Simcere leadership, the collaboration aligns with the company’s Innovation 2.0 strategy, which focuses on building a sustainable pipeline of globally competitive therapies through external partnerships and breakthrough scientific research. By securing future worldwide rights to the resulting therapeutic candidate, Simcere strengthens its long-term position in respiratory medicine while expanding opportunities for global commercialization.
The partnership also reinforces a broader industry trend toward integrating academic innovation with pharmaceutical development expertise to accelerate the discovery of transformative therapies. If successful, the collaboration could lead to a novel treatment option for IPF patients worldwide and further establish Simcere as an emerging leader in first-in-class drug development.
Source: Simcere Pharmaceutical press release
